Other
Neoadjuvant
0
Pipeline Programs↗
23
Active Trials↗
3
Companies Involved↗
Neoadjuvant is an early-stage landscape with 0 programs across 3 companies. The most active players are Novartis, Bristol-Myers Squibb, AstraZeneca.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
60
clinical trials
Completed17 · 28%
Recruiting14 · 23%
Terminated9 · 15%
Active, not recruiting8 · 13%
Unknown status7 · 12%
Withdrawn3 · 5%
Other2 · 3%
Clinical Trials
Trial Activity
60 trials
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
Recruiting·—·Phase 1·NCT05839119·32 enrolled
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Recruiting·—·Phase 2·NCT07016399·51 enrolled
Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04848116·24 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)